Logo

Lilly's Bebtelovimab Receives the US FDA’s EUA for Mild-to-Moderate COVID-19

Share this

Lilly's Bebtelovimab Receives the US FDA’s EUA for Mild-to-Moderate COVID-19

Shots:

  • The EUA was based on P-II BLAZE-4 trial assessing bebtelovimab (175 mg) alone or together with bamlanivimab (700mg) and etesevimab (1400mg) in non-hospitalized patients with mild-to-moderate COVID-19 
  • Pseudovirus and authentic virus testing showed that bebtelovimab retains full neutralizing activity against Omicron. Additionally, pseudovirus testing unveiled that it retains neutralization against all other known variants of interest and concern, including BA.2
  • Lilly will supply up to 600,000 doses of investigational drug bebtelovimab for at least $720M, as per the agreement signed with the US government

 Ref: Lilly | Image: Wall Street Journal

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions